Alyeska Investment Group, L.P. Blueprint Medicines Corp Transaction History

Alyeska Investment Group, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $5.43 Million - $7.54 Million	95,124 Added 47.15%	296,858 $23.2 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $7.77 Million - $13.3 Million	161,482 Added 401.18%	201,734 $11.8 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $8.63 Million - $10.7 Million	-129,253 Reduced 76.25%	40,252 $3.22 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $2.42 Million - $4.31 Million	49,747 Added 41.54%	169,505 $0
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $2.78 Million - $4.61 Million	45,602 Added 61.49%	119,758 $7.6 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $268,571 - $377,311	3,665 Added 5.2%	74,156 $6.8 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $1.86 Million - $2.61 Million	-29,509 Reduced 29.51%	70,491 $5.32 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $4.24 Million - $6.97 Million	100,000	100,000 $6.97 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.57B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.